Key result
Regional citrate anticoagulation shows promise as a replacement for heparin across routine hemodialysis procedures.
Answers are grounded in this paper and cite their sources.
Citrate has many characteristics of the ideal anticoagulant for hemodialysis. In addition to immediate and complete anticoagulation in the dialysis circuit, citrate has important effects beyond anticoagulation, mainly in reducing inflammatory response induced by hemodialysis. Citrate has already become the standard anticoagulant in acute kidney injury requiring continuous renal replacement therapy (CRRT), both for adults and children, with the citrate module being a part of modern CRRT monitors. Although the citrate module is not yet available for intermittent hemodialysis, precise infusion pumps, point-of-care ionometers and high citrate clearance from high flux dialyzers increase safety while reducing the risk of metabolic complications, both in adult and pediatric patients. Slovenia has a long tradition, high volume and expansion of citrate use in hemodialysis, including long-term citrate anticoagulation in selected patients. At the Department of Nephrology, University Medical Centre Ljubljana, more than 10 000 citrate procedures were performed in 2015. We believe that regional citrate anticoagulation may replace heparin as the main anticoagulant for intermittent hemodialysis in the not so distant future.
No takes yet. Share an insight, caveat, or question.
Jadranka Buturović‐Ponikvar (2016) conducted a review in Acute kidney injury and hemodialysis. Regional citrate anticoagulation vs. Heparin was evaluated. Regional citrate anticoagulation was used in >10,000 hemodialysis procedures in 2015 at a Slovenian center and may replace heparin as the primary anticoagulant.
Synapse has enriched 10 related papers. Consider them for comparative context: